支气管镜下肺泡灌洗阿米卡星治疗老年支气管扩张合并感染患者的疗效

doi:10.3969/j.issn.1000-8535.2022.06.007

摘要/Abstract

摘要： 目的探究支气管镜下肺泡灌洗并局部使用阿米卡星治疗老年支气管扩张合并感染患者的疗效及对血清炎性因子水平的影响。方法选取我院2018年3月—2019年5月确诊支气管扩张症、合并感染的符合纳入标准的患者共64例,按照1:1比例抽签分为2组,32例纳入观察组,应用支气管镜下肺泡灌洗阿米卡星治疗;32例纳入对照组,以单纯的支气管镜下肺泡灌洗治疗。观察并比较2组患者的治疗效果、血清炎性因子水平、肺功能情况等。结果疗效比较显示观察组的96.9%总有效率高于对照组的75.0%(P＜0.05);血清炎性因子水平在患者用药前检测无差异(P＞0.05),经过治疗后,观察组水平均优于对照组P＜0.05;经治疗后,观察组静态肺活量、补呼气量、补吸气量、用力肺活量均优于对照组,差异具有统计学意义(P＜0.05)。结论对老年支气管扩张合并感染患者应用支气管镜下肺泡灌洗阿米卡星治疗,促进临床效果改善,患者的症状、炎症及肺功能等指标均得到明显改善,值得推广。

关键词: 阿米卡星, 支气管镜下肺泡灌洗, 支气管扩张, 感染, 疗效, 血清炎性因子水平

Abstract: Objective To investigate the efficacy of bronchoscopic alveolar lavage and local application of amikacin in the treatment of elderly patients with bronchiectasis complicated with infection and its effect on the level of serum inflammatory factors.Methods A total of 64 patients with bronchiectasis complicated with infection diagnosed in our hospital from March 2018 to May 2019 were selected.They were divided into two groups evenly by proportional drawing. Thirty-two cases were included in the observation group that were treated with bronchoscopic alveolar lavage with amikacin.The other 32 cases were included in the control group that were treated with the bronchoscopic alveolar lavage only.The therapeutic effect,serum inflammatory factor level and pulmonary function of the two groups were observed and compared.Results The total effective rate of 96.9% in observation group was higher than 75.0% in control group (P<0.05).There was no difference in the levels of serum inflammatory factors before treatment (P>0.05).After treatment,the levels of the observation group were better than those of the control group (P<0.05).After treatment,the slow vital capacity,expiratory reserve volume,inspiratory reserve volume and forced vital capacity of the patients in the observation group were better than those in the control group (P<0.05).Conclusions Bronchoscopic alveolar lavage of amikacin in elderly patients with bronchiectasis complicated with infection could improve the clinical effect.The symptoms of the patients,the serum inflammatory factors and lung function of the patients were significantly improved.The treatment is worthy of promotion.

Key words: amikacin, bronchoscopic alveolar lavage, bronchiectasia, infection, curative effect, serum inflammatory factor level

黄娟, 温雅, 张华根, 朱旭华, 曾汉华. 支气管镜下肺泡灌洗阿米卡星治疗老年支气管扩张合并感染患者的疗效[J]. 广州医药, 2022, 53(6): 31-35.

HUANG Juan, WEN Ya, ZHANG Huagen, ZHU Xuhua, ZENG Hanhua. Effect of bronchoscopic alveolar lavage with amikacin in elderly patients with bronchiectasis complicated with infection[J]. Guangzhou Medical Journal, 2022, 53(6): 31-35.

参考文献

[1] CHANDRASEKARAN R,MAC AOGÁIN M,CHALMERS J D,et al.Geographic variation in the aetiology,epidemiology and microbiology of bronchiectasis[J].BMC Pulm Med,2018,18(1):83.
[2] 支气管扩张症专家共识撰写协作组,中华医学会呼吸病学分会感染学组,瞿介明,等.中国成人支气管扩张症诊断与治疗专家共识[J].中华结核和呼吸杂志,2021,44(4):311-321.
[3] KIM H C,SUZUKI M,LIM H F,et al.Survey of the management of patients with bronchiectasis: a pilot investigation in Asian populations[J].Korean J Intern Med,2021,36(6):1402-1409.
[4] 徐金富.推动支气管扩张症的精准化诊治和规范化管理[J].中华结核和呼吸杂志,2021,44(4):283-286.
[5] 何权瀛.成人支气管扩张症诊治专家共识[J].中华结核和呼吸杂志,2012(7):485-492.
[6] 中华医学会呼吸病学分会介入呼吸病学学组.成人诊断性可弯曲支气管镜检查术应用指南(2019年版)[J].中华结核和呼吸杂志,2019,42(8):573-590.
[7] SIN S,YUN S Y,KIM J M,et al.Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis[J].Respir Res,2019,20(1):271.
[8] 徐小勇,施毅.支气管扩张的诊断和治疗进展[J].中国呼吸与危重监护杂志,2017,16(2):186-190.
[9] 姬新珂,冯莉莉,申艳光,等.肺泡灌洗治疗支气管扩张合并感染临床疗效和安全性的系统评价[J].医学综述,2020,26(11):2261-2269.
[10] 屈蕾蕾,边雨田,张衡中,等.阿米卡星联合支气管镜下肺泡灌洗治疗老年支气管扩张合并感染患者的疗效及对血清炎性因子水平的影响[J].内科,2018,13(4):588-591,632.
[11] 周卜全,李新科.阿米卡星对老年支气管扩张症及黏液分泌过多患者的治疗效果[J].实用医学杂志,2017,27(6):1066-1068.
[12] 帅冬怡,廖慧娟.阿米卡星治疗老年支气管扩张症及黏液分泌过多患者的效果[J].中国老年学杂志,2015,(14):3943-3944.
[13] 孙美玉.阿米卡星口服治疗老年支气管扩张症并黏液高分泌的临床价值分析[J].中国医药指南,2017,(19):113-114.
[13] 余静珠,居健惠,孙锦贤,等.疏风解毒胶囊联合桔芩汤治疗29例支气管扩张急性期临床观察[J].上海医药,2016,37(6):24-27.
[14] 唐忆贫.阿米卡星对老年支气管扩张症及黏掖分泌过多的疗效分析[J].中国当代医药,2018,19(1):57,59.
[15] 张学平,马小芬,赵娜,等.支气管肺泡灌洗阿米卡星治疗支气管扩张感染的临床疗效及对炎症因子的影响[J].滨州医学院学报,2018,190(2):40-42.
[16] 成人抗感染药物下呼吸道局部应用专家共识[J].中华结核和呼吸杂志,2021,44(4):322-339.
[17] 屈蕾蕾,边雨田,张衡中.厄多司坦联合支气管镜下肺泡灌洗治疗老年支气管扩张合并感染患者的疗效及对血清炎性因子水平的影响[J].内科,2018,13(4):588-591,632.
[18] 姜涛,陈帅.支气管肺泡保留灌洗联合阿奇霉素序贯治疗在支气管扩张合并感染患者中的应用[J].世界最新医学信息文摘,2019,19(81):141,143.
[19] 钟英豪,梁红卫,陈秀珍.左氧氟沙星联合阿米卡星经气管镜下注药治疗支气管扩张的临床观察[J].中国医药科学,2020,10(7):65-68.
[20] 张杨,田竟,张红梅,等.纤支镜支气管肺泡灌洗+依替米星对老年重症支气管扩张合并感染患者症状改善及肺功能的影响[J].临床医学研究与实践,2020,5(17):14-16.
[21] 吴燕廷,李淑媚.异帕米星局部用药联合支气管肺泡灌洗治疗老年支气管扩张感染的疗效分析[J].海峡药学,2020,32(11):156-158.
[22] 刘晓黎.纤维支气管镜肺泡灌洗联合哌拉西林舒巴坦钠治疗支气管扩张症并感染患者的疗效评价[J].河南医学研究,2021,30(12):2199-2201.
[23] 周笳,谭效锋,董丽霞.支气管扩张症继发感染的病原学及影响因素分析[J].中华医院感染学杂志,2019,29(24):3764-3768.
[24] 符标,黄达.成年人支气管扩张症急性加重期呼吸道病原谱特点以及与疾病严重度的关联分析[J].中国医师进修杂志,2020,43(10):868-872.
[25] 迟妍,李星,马震,等.支气管扩张症合并多药耐药铜绿假单胞菌感染患者的炎症免疫指标特点[J].中国老年学杂志,2019,39(21):5262-5264.
[26] 徐金富,柴燕华.支气管扩张症患者下呼吸道分离出铜绿假单胞菌的临床意义和对策[J].中华结核和呼吸杂志,2019(7):506-509.
[27] 刘海燕,殷瑜.氨基糖苷类抗生素作用机制研究进展[J].中国抗生素杂志,2019,44(11):1283-1287.
[28] 许桓,唐春雷,范为正.氨基糖苷类抗生素的研究进展[J].中国新药杂志,2019,28(15):1828-1835.
[29] 丁武君,姚晓燕,杨戎威.纤维支气管镜肺泡灌洗治疗新生儿重症肺炎的临床效果[J].中国医药导报,2019,16(9):94-97.
[30] 程耀强,陀子能.支气管镜肺泡灌洗治疗支气管扩张症的临床疗效[J].慢性病学杂志,2019,20(10):1502-1503.
[31] 刘青.经支气管镜不同容量灌洗治疗支气管扩张症并感染的效果比较[J].黑龙江中医药,2019,48(6):192-193.
[32] 周志亮.纤维支气管镜吸痰联合支气管肺泡灌洗在支气管扩张合并感染治疗中的临床价值研究[J].中国现代药物应用,2021,15(14):38-40.
[33] 李波.支气管镜下肺泡灌洗对支气管扩张并感染者的疗效及对感染指标的影响研究[J].临床研究,2021,29(10):62-63.
[34] 樊勋,黎燕妹,李成志,等.血清降钙素原、C反应蛋白水平对急性加重期支气管扩张治疗中抗生素应用的参考价值[J].临床医学工程,2019,26(5):627-628.
[35] 韩飞.血清降钙素原、C反应蛋白水平对急性加重期支气管扩张治疗中抗菌素应用的参考价值分析[J].齐齐哈尔医学院学报,2016,37(22):2796-2797.